



Dear Molina Healthcare Provider,

The enclosed letter explaining the Molina formulary deletions occurring on May 1, 2005 was mailed to you in late March. A similar communication was distributed to members at approximately the same time. Reasons for implementing the OxyContin deletion, in particular, include the following:

- The potential for OxyContin abuse and diversion.
- A number of members filling prescriptions for exorbitant amounts of OxyContin with few if any other pain management methods attempted.
- Lack of incentive to prescribe more economical long-acting opioid alternatives.

Since a “grandfather period” will generally not be allowed, we encourage you to contact the members on the enclosed list as soon as possible who filled at least one OxyContin prescription written by you since January 1, 2005. Converting patients now to other similar long-acting opioid analgesics (e.g., sustained-release morphine, fentanyl patches) would be most helpful so as to avoid confusion and misunderstandings at the retail pharmacy once the formulary change date of May 1 occurs.

A very limited number of members will be able to continue filling OxyContin prescriptions based on the following criteria:

Requests for continuation of OxyContin:

Diagnosis of terminal cancer

Documented morphine allergic reaction (i.e., rash, anaphylaxis) **OR**

Documented minimum 3-month trial of long-acting morphine, fentanyl patches or methadone in combination with short-acting opioids proved ineffective.

New OxyContin requests:

Documented minimum 3-month trial/failure of long-acting morphine, fentanyl patches or methadone as outlined above.

Please contact Customer Service at (888) 825-9266 or the Pharmacy Prior Authorization Line at (888) 884-9527 if we can be of assistance with your patient conversion issues. Thank you for your cooperation in this matter.

Sincerely,

A handwritten signature in black ink that reads "Ann O Wehr MD".

Ann O. Wehr, MD
Chief Medical Officer

A handwritten signature in black ink that reads "David A. Havlovic".

David A. Havlovic, Pharm.D.
Pharmacy Director